Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Xx. x. x. x x. 46/2008 Xx. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx dopingu pro xxx 2018 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx xxxxx dopingu xx sportu¹⁾.

S novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx republiky xxxxxxxx xxxxxxx x přijetí xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Českou xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx X x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx nového xxxxx Xxxxxxx I x xxxxxxxx přestalo xxxxxx xxxxx Přílohy I xxxxxx od 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx znění Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX XXX 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx text Seznamu xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x angličtině a xxxxxxxxxxxxx.

X xxxxxxx jakýchkoliv xxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx bude xxxxxx xx 1. xxxxx 2018 

SEZNAM ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX ROK 2018

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2018

XXXXX A XXXXXX XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX SOUTĚŽ)

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx výzkumu xxxx po xxxxxxxx xxxxxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-hydroxy-5α-androst-1-en-3-on);

tetrahydrogestrinon (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:

Androstanolon (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx na ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, LGD-4033, ostarin x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

Xxx xxxxx skupiny xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx tělo xxxxxxxx xxxxxxxxx produkuje.

S2. PEPTIDOVÉ XXXXXXX, RŮSTOVÉ FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, xxx ne x omezením pouze xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptoru, např

darbepoetiny (xXXX); erytropoetiny (XXX); xxxxxxxxxx xxxxxxxx xx XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); EPO-mimetické xxxxxxxxxx a xxxxxx xxxxxxxxxx (např. CNTO 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xenon.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, gonadorelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx, x xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (GH), xxxx xxxxxxxxx x uvolňující xxxxxxx, včetně, xxx xx s xxxxxxxx xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxx. CJC-1295, xxxxxxxxxx x xxxxxxxxxxx; sekretagogy xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, ipamorelin a xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (GHRP), xxxx. alexamorelin, XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx s xxxxxxxx xxxxx na xx:

xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx);

xxxxxxxxxxxx růstový xxxxxx (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx analoga

mechanické xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. TB-500;

vaskulárně-endoteliární růstový xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3. XXXX2- AGONISTÉ

Všichni xxxxxxxxxx i neselektivní xxxx-2 xxxxxxxx, včetně xxxxx optických xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; indakaterol; xxxxxxxxxx; xxxxxxxxxx; reproterol; xxxxxxxxxx; xxxxxxxxxx; terbutalin; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx v xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx během xxxxxxx 12 hodin po xxxxxxxxx dávce;
• inhalační xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x xxxxxxxxxx formoterolu x moči v xxxxxxxxxxx vyšší xxx 40 ng/ml xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (v xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx jsou xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), zahrnující:

Raloxifen;

tamoxifen;

toremifen, xxx xx x xxxxxxxx xxxxx na xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.

4. Xxxxx modifikující funkci(e) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) kyselina xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx látky xxxx xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx); xxxxxxxxxx, ale xx x omezením xxxxx xx ně.

• Acetazolamid; xxxxxxxx; bumetanid; xxxxxxxxx; xxxxxxxxxxxx; indapamid; xxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), ale xx s xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (např. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (tj. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx kdykoliv xxxx xxxxxxxx Xxx Soutěži xx spojení x xxxxxxxxxx xxxx jinou xxxxxxxxx látkou, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx nález, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx xxxxx xxxxx k té, xxxxx již xxxx xxxxxxx na xxxxxxxxxx xxxx xxxxx maskovací xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ A XXXXXXXX KOMPONENTAMI

Zakázané je xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv množství xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx červených krvinek x xxx podobných xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x omezením xxxxx xx ně. Xxxxxxxxx xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx komponentami fyzikálními xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je následující:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:

1. Použití xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx k xxxxxxxxxxx sekvencí genomu x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx S5 x X1 až X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx zakázaná.

Stimulancia zahrnují:

(a) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (xxx xx s xxxxxxxx xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx a xxxx xxxxxxx (xxxx. xxxxxxxx, methedron a xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S výjimkou:

• klonidinu

• derivátů xxxxxxxxx v xxxxxxx xxxxxx místního/očního xxxxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: Xxxx xxxxx xxxx zahrnuté xx Monitorovacího programu 2018 a xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší xxx 5 mikrogramů x 1 ml moči.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx v 1 xx moči.

**** Xxxxxxxxx (epinefrin): není xxxxxxx xxx lokálním xxxxxx, xxxx. xxxxx, xxxx aplikace xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: je zakázán, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx xxx 150 xxxxxxxxxx na mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující kanabinoidy xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. hašiš, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou zakázané.

Včetně, xxx ne s xxxxxxxx xxxxx na xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x kde xx to xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx na lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, a xxxxxxxxx U-rampa x "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx xxxxxxxx) (CMAS) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx bez ploutví, xxxxxxxxx xxxxx s xxxxxxxxx nebo bez xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx také Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne s xxxxxxxx xxxxx xx xx.

Informace

Právní předpis č. 36/2019 Xx. x. x. xxxxx xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. s. xxx xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx se jich xxxxxx derogační xxxxx xxxxx uvedeného právního xxxxxxxx.

1) Xxxxxxxxxxx úmluva xxxxx xxxxxxx xx xxxxxx, přijatá xxx 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x s xxxxxxxxx do českého xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Úmluvy xx xxxxxxx xxxxxx xxxx vyhlášeno pod č. 46/2008 Sb. m. s.